[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020003834A - Composiciones acuosas que comprenden bilastina y mometasona. - Google Patents

Composiciones acuosas que comprenden bilastina y mometasona.

Info

Publication number
MX2020003834A
MX2020003834A MX2020003834A MX2020003834A MX2020003834A MX 2020003834 A MX2020003834 A MX 2020003834A MX 2020003834 A MX2020003834 A MX 2020003834A MX 2020003834 A MX2020003834 A MX 2020003834A MX 2020003834 A MX2020003834 A MX 2020003834A
Authority
MX
Mexico
Prior art keywords
bilastine
mometasone
pharmaceutical composition
relates
aqueous pharmaceutical
Prior art date
Application number
MX2020003834A
Other languages
English (en)
Inventor
Herrero Gonzalo Hernández
Domínguez Neftalí García
Gorostiza Ana Gonzalo
Arce Arturo Zazpe
Poladura Pablo Morán
García Tania González
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of MX2020003834A publication Critical patent/MX2020003834A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)

Abstract

La invención se refiere a una composición farmacéutica acuosa que comprende a) bilastina o una sal o un solvato farmacéuticamente aceptable de la misma, b) mometasona, o un derivado farmacéuticamente aceptable de la misma, c) un agente de suspensión, y d) 2-hidroxipropil-?-ciclodextrina; en la que el pH de la composición farmacéutica acuosa es de entre 3,5 y 5,5, y en la que el contenido de 2-hidroxipropil-?-ciclodextrina es de menos del 8,5% en peso. La invención también se refiere a dichas composiciones para su uso en el tratamiento y/o la prevención de un trastorno o una enfermedad susceptible de mejora por antagonismo del receptor de histamina H1 y/o de una enfermedad que responde a los corticoesteroides a través de administración nasal. La invención también se refiere a un procedimiento para preparar la composición farmacéutica acuosa mencionada anteriormente.
MX2020003834A 2017-10-16 2018-10-15 Composiciones acuosas que comprenden bilastina y mometasona. MX2020003834A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17382686 2017-10-16
PCT/EP2018/078034 WO2019076798A1 (en) 2017-10-16 2018-10-15 AQUEOUS COMPOSITIONS COMPRISING BILASTIN AND MOMETASONE

Publications (1)

Publication Number Publication Date
MX2020003834A true MX2020003834A (es) 2020-08-06

Family

ID=60262869

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003834A MX2020003834A (es) 2017-10-16 2018-10-15 Composiciones acuosas que comprenden bilastina y mometasona.

Country Status (23)

Country Link
US (1) US11642309B2 (es)
EP (1) EP3681475B1 (es)
JP (1) JP2020536972A (es)
KR (1) KR20200125923A (es)
CN (1) CN111526869A (es)
AU (1) AU2018353360B2 (es)
BR (1) BR112020007569A2 (es)
CA (1) CA3079303A1 (es)
CO (1) CO2020005939A2 (es)
DK (1) DK3681475T3 (es)
EA (1) EA202090965A1 (es)
ES (1) ES2858573T3 (es)
HR (1) HRP20210260T1 (es)
HU (1) HUE053233T2 (es)
IL (1) IL273967A (es)
LT (1) LT3681475T (es)
MA (1) MA50247B1 (es)
MX (1) MX2020003834A (es)
PL (1) PL3681475T3 (es)
PT (1) PT3681475T (es)
SG (1) SG11202003384XA (es)
TW (1) TW201922250A (es)
WO (1) WO2019076798A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201918617D0 (en) * 2019-12-17 2020-01-29 Reckitt Benckiser Health Ltd Personal lubricant composition

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2048109B1 (es) 1992-07-20 1994-12-16 Espanola Prod Quimicos Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol.
DE4426709A1 (de) 1994-07-20 1996-01-25 Schering Ag Steroidale Sexualhormone enthaltende feste Arzneiformen
ES2124167B1 (es) 1996-06-04 1999-09-16 Espanola Prod Quimicos Nuevos derivados del bencimidazol con actividad antihistaminica.
FR2780901B1 (fr) * 1998-07-09 2000-09-29 Coletica Particules, en particulier micro- ou nanoparticules de monosaccharides et oligosaccharides reticules, leurs procedes de preparation et compositions cosmetiques, pharmaceutiques ou alimentaires en contenant
GB0312148D0 (en) * 2003-05-28 2003-07-02 Aventis Pharma Ltd Stabilized pharmaceutical products
US20060045850A1 (en) 2004-08-30 2006-03-02 Qpharma, Llc Nasal delivery of cyclodextrin complexes of anti-inflammatory steroids
EP1896086A1 (en) 2005-06-30 2008-03-12 Bristol-Myers Squibb Pharma Company Hydrazide conjugates as imaging agents
US20070082870A1 (en) 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
EP1894559A1 (en) 2006-09-01 2008-03-05 PARI Pharma GmbH Means to solubilise steroids for inhalation
CN101273993A (zh) * 2007-03-27 2008-10-01 北京亚欣保诚医药科技有限公司 糠酸莫米松溶液型液体制剂
ES2493641T3 (es) 2007-06-28 2014-09-12 Cydex Pharmaceuticals, Inc. Administración nasal de soluciones acuosas de corticosteroides
PT2173169E (pt) * 2007-06-28 2014-09-03 Cydex Pharmaceuticals Inc Entrega nasal de soluções de corticosteróide aquosas
CN101756998A (zh) * 2008-11-28 2010-06-30 天津金耀集团有限公司 采用环糊精包合糠酸莫米松的鼻用药物组合物
CN201373609Y (zh) 2009-03-13 2009-12-30 潘戈 太阳能集热器箱体
CA2764473A1 (en) 2009-06-05 2010-12-09 Aciex Therapeutics, Inc. Ophthalmic formulations of fluticasone and methods of use
KR101304341B1 (ko) 2011-09-19 2013-09-11 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물
US9629847B2 (en) 2011-11-23 2017-04-25 Michael Leighton Compositions and methods for treating symptoms of inflammatory related conditions using a combination of an antihistamine and a stimulant
CN103736098A (zh) * 2013-12-27 2014-04-23 于运红 一种含有比拉斯汀及糠酸莫米松的鼻内给药用药物组合物
CN103784462A (zh) * 2014-02-25 2014-05-14 宋俊智 包含比拉斯汀及甾族化合物的药物制剂
EP3040334A1 (en) 2014-12-29 2016-07-06 Faes Farma, S.A. New benzimidazole derivatives as antihistamine agents
WO2016141219A1 (en) 2015-03-05 2016-09-09 Cosmederm Bioscience, Inc. Strontium based compositions and formulations for pain, pruritus, and inflammation
EP3323173B8 (en) * 2015-07-15 2020-10-07 TE Connectivity Services GmbH Conductive bar with annular portion to accommodate test plug
EP3170816A1 (en) 2015-11-20 2017-05-24 Faes Farma, S.A. Supersaturated compositions of benzimidazole compounds

Also Published As

Publication number Publication date
PL3681475T3 (pl) 2021-07-05
MA50247B1 (fr) 2021-02-26
DK3681475T3 (da) 2021-02-01
AU2018353360A1 (en) 2020-05-07
EP3681475B1 (en) 2020-12-09
HUE053233T2 (hu) 2021-06-28
CA3079303A1 (en) 2019-04-25
SG11202003384XA (en) 2020-05-28
AU2018353360B2 (en) 2021-04-01
BR112020007569A2 (pt) 2020-09-24
HRP20210260T1 (hr) 2021-04-02
TW201922250A (zh) 2019-06-16
IL273967A (en) 2020-05-31
CO2020005939A2 (es) 2020-10-30
MA50247A (fr) 2020-07-22
CN111526869A (zh) 2020-08-11
US11642309B2 (en) 2023-05-09
US20210186869A1 (en) 2021-06-24
WO2019076798A1 (en) 2019-04-25
KR20200125923A (ko) 2020-11-05
EA202090965A1 (ru) 2020-07-22
JP2020536972A (ja) 2020-12-17
ES2858573T3 (es) 2021-09-30
PT3681475T (pt) 2021-03-08
EP3681475A1 (en) 2020-07-22
LT3681475T (lt) 2021-02-25

Similar Documents

Publication Publication Date Title
GT201700056A (es) Uso de agonista dual del receptor de glp-1/glucagón de acción prolongada para el tratamento de la enfermedad del hígado graso no alcohólico.
CL2019003542A1 (es) Métodos de tratamiento para la fibrosis quística.
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
NZ723838A (en) Cannabinoid compositions and uses
EA202191498A1 (ru) 9-замещенные производные аминотриазолохиназолина в качестве антагонистов аденозиновых рецепторов, фармацевтические композиции и их применение
CL2018001510A1 (es) Composición farmacéutica que comprende un potente inhibidor de urat1
AR108046A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
CO2018004206A2 (es) Formulación farmacéutica para administración oral que comprende un compuesto de 25-hidroxi vitamina d”
EA201692388A1 (ru) Лекарственная форма в виде множества частиц, защищенная от вызываемого этанолом сброса дозы
CO2016003340A2 (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2019000625A1 (es) Combinación de agonistas de fxr.
CO2017005806A2 (es) Nuevos derivados de bencimidazol como agentes antihistamínicos
CO2020005939A2 (es) Composiciones acuosas que comprenden bilastina y mometasona
MX2023006235A (es) Composiciones para administracion de farmacos y metodos de uso de las mismas.
CO2020009992A2 (es) Composiciones oftálmicas que comprenden bilastina, una beta-ciclodextrina y al menos un agente de gelificación
ECSP19027578A (es) Composición farmacéutica con antagonista del receptor de mineralocorticoides y su uso
BR112017025527A2 (pt) preparação farmacêutica líquida, e, método para fabricar uma suspensão de celocoxibe.
BR112019005578A2 (pt) compostos de indazol para uso em lesões no tendão e/ou ligamento
PE20190347A1 (es) Formulaciones inyectables fisiologicamente balanceadas de fosnetupitant
AR107935A1 (es) Uso del compuesto 6-(4-(2,3-dimetilfenoxi)piperidin-1-il)metil)pirimidino-2,4(1h,3h)-diona o una sal farmacéuticamente aceptable del mismo para preparar un medicamento, combinación y composición farmacéutica que comprende dicho compuesto
AR111699A1 (es) Composición farmacéutica que comprende betahistina
MX2019007360A (es) Derivado de triazol azabiciclo-sustituido, preparacion, metodo del mismo, y aplicacion de la misma en medicina.
EA201890789A1 (ru) Содержащая цинеол композиция для лечения заболеваний носа
BR112021020694A2 (pt) Composições farmacêuticas de bilastina estáveis e preservadas